Presentation is loading. Please wait.

Presentation is loading. Please wait.

Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director, BC-Centre for Excellence in HIV/AIDS at Providence.

Similar presentations


Presentation on theme: "Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director, BC-Centre for Excellence in HIV/AIDS at Providence."— Presentation transcript:

1 Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director, BC-Centre for Excellence in HIV/AIDS at Providence Health Care UNAIDS Special Advisor on HIV Therapeutics Treatment as Prevention The Key to Eliminate AIDS & HIV AU EDITED FINAL: Special Technical Satellite, Melbourne 2014

2 The promise of HIV treatment: 1.Prevent HIV-related illness and disability 2.Avert AIDS-related deaths 3.Prevent new HIV infections

3 Increasing HAART Coverage within Evolving Guidelines in BC Source: Montaner et al, Lancet, 2010 January 2004 Summer of 1996 Summer of 2000 Phase I Phase II Phase III # of active participants on HAART in the HIV treatment programme

4 Source: Montaner et al, 2014 New AIDS Cases Diagnosed by Year British Columbia to 2013

5 > 90% Decrease in All Cause Mortality among HIV+ Individuals in BC, Canada since Years Frequency Source: Montaner et al, PLOS One, 12 Feb 2014

6 Source: Montaner et al, International AIDS Conference, 2014, Poster # TUPE203 New HIV Cases Diagnosed, Estimated HIV Incidence, & HAART Use by Year in BC

7 A clear correlation exists between HIV treatment and incidence Source: Tanser et al. Science 2013;339: % (0.8%-1.4%) reduction in HIV incidence, for each 1.0% increase in treatment coverage. ART & HIV incidence: Hlabisa, South Africa p=0.325 p=0.003 p=0.013 p= Incidence rate ratio ART coverage 0%30%60%

8 HIV incidence vs. ART coverage in 51 countries, weighted by epidemic size (2012 data) AIDS-related death rates vs. ART coverage in 51 countries, weighted by epidemic size (2012 data) Source: Hill, Pozniak, Raymond, Heath and Ford, AIDS 2014, 2014.

9 HIV Transmission According to Sexual Behavior Reported by HIV-Negative Partner Rate of Couple Transmission (per 100 Couple-Years Follow-Up) Heterosexual (Male) Vaginal sex with ejaculation (192 CYFU) Heterosexual (Female) Vaginal sex (272 CYFU) MSM Receptive anal sex: With ejaculation (93 CYFU) Without ejaculation (157 CYFU) Insertive anal sex (262 CYFU) Rate (95% CI) Overall risk = Zero through condomless sex with a partner on ART (HIV RNA <200 copies/mL Source: Rodger A, et al. 21 st CROI. Boston, Abstract 153LB

10 HIV treatment: The most effective biomedical intervention for the prevention of HIV transmission

11 Expanding ART for treatment and prevention of HIV in South Africa: Cost-effectiveness Lives Saved (x 1,000)U$A Billions Source: Granich et al, PLoS ONE 7(2):e30212, February 2013

12 By 2020… 90% of all people living with HIV will know their HIV status 90% of all people diagnosed with HIV will receive sustained antiretroviral therapy. 90% of all people receiving antiretroviral therapy will have durable suppression.

13 The result = a three-fold increase over current 2014 estimates 72 % of all people living with HIV will be virally suppressed 3

14 The new treatment paradigm Single target → Cascade target Death → Death and transmission Number → Equity Incremental funding→ Frontload Investments

15 The objective “Maximize the effectiveness of existing tools to virtually eliminate progression to AIDS, premature death and HIV transmission, and thereby transform the HIV/AIDS pandemic into a low level sporadic endemic.”

16 THE FINAL CHAPTER OF THE AIDS EPIDEMIC


Download ppt "Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director, BC-Centre for Excellence in HIV/AIDS at Providence."

Similar presentations


Ads by Google